Iguratimod , ≥98% , 123663-49-0

Synonym(s):
3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one;IGU;N-(7-(Methylsulfonamido)-4-oxo-6-phenoxy-4H-chromen-3-yl)formamide;N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide;T-614

CAS NO.：123663-49-0

Empirical Formula: C17H14N2O6S

Molecular Weight: 374.37

MDL number: MFCD00882374

EINECS: 808-127-0

PRODUCT Properties

• Melting point: 238.0 to 242.0 °C
• Boiling point: 580.6±60.0 °C(Predicted)
• Density: 1.52±0.1 g/cm3(Predicted)
• storage temp.: under inert gas (nitrogen or Argon) at 2-8°C
• solubility: DMSO (Slightly)
• form: Solid
• pka: 5.58±0.20(Predicted)
• color: White to Off-White

Description and Uses

In August 2011, China’s State FDA approved Simcere Pharmaceutical Group’s new drug application for iguratimod (T-614), a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced arthritis model in DBA/1J mice at 30 mg and 100 mg/kg.

Iguratimod acts as an anti-inflammatory agent, used primarily in the treatment of rheumatoid arthritis.

Safety

• Symbol(GHS): GHS08
• Signal word: Warning
• Hazard statements: H361
• Precautionary statements: P501-P202-P201-P280-P308+P313-P405
• HS Code: 2935.90.9500